Social Network
Pfizer begins Phase 2/3 study for COVID-19 oral antiviral in exposed adults
September 28 2021, 08:00
Pfizer initiated a Phase 2/3 study of an investigational oral antiviral with a low dose of ritonavir to prevent COVID-19 illness, the company announced Monday.